Efficacy of DNK333 in Patients With COPD and Cough

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the efficacy and safety of two weeks treatment of DNK333 in patients with COPD and cough.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis

Criteria

Inclusion Criteria:

• Mild to moderate COPD

• Forced expiratory volume in 1 second (FEV1) ≥30% predicted

• FEV1/FVC (forced vital capacity) <70%

• Significant amount of cough and minimal amount of sputum production, both as judged by self reporting

Exclusion criteria:

• Upper or lower airway infection within 4 weeks prior to screening

• COPD exacerbation within 4 weeks prior to screening

• Past history or current diagnosis of congestive heart failure, cirrhosis or hepatic failure

• History of lung cancer or pulmonary resection/thoracic radiotherapy

Other protocol-defined inclusion/exclusion criteria may apply